Literature DB >> 3379071

Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia.

J R Mickelson1, E M Gallant, L A Litterer, K M Johnson, W E Rempel, C F Louis.   

Abstract

Previous studies have demonstrated that skeletal muscle from individuals susceptible to malignant hyperthermia (MH) has a defect associated with the mechanism of calcium release from its intracellular storage sites in the sarcoplasmic reticulum (SR). In this report we demonstrate that the [3H]ryanodine receptor of isolated MH-susceptible (MHS) porcine heavy SR exhibits an altered Ca2+ dependence of [3H]ryanodine binding at the low affinity Ca2+ site as well as a lower Kd for ryanodine (92 versus 265 nM) when compared to normal porcine SR. The Bmax of the normal and MHS [3H] ryanodine receptor (9.3-12.6 pmol/mg) was not significantly different, and analysis of MHS and normal SR proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis did not reveal a significant difference in the intensity of Coomassie Blue staining of the spanning protein/ryanodine receptor region of the gels (Mr greater than 300,000). We also find that MHS porcine muscle intact fiber bundles exhibit a 5-10-fold lower ryanodine threshold for twitch and tetanus inhibition, and contracture onset when compared to normal muscle. Since the SR ryanodine receptor is a calcium release channel as well as a component intimately involved in transverse tubule-SR communication, abnormalities in the skeletal muscle ryanodine receptor may be responsible for the abnormal SR calcium release and contractile properties demonstrated by MHS muscle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379071

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.

Authors:  K E Keating; L Giblin; P J Lynch; K A Quane; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

Review 2.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

Review 3.  Ion conduction and discrimination in the sarcoplasmic reticulum ryanodine receptor/calcium-release channel.

Authors:  A J Williams
Journal:  J Muscle Res Cell Motil       Date:  1992-02       Impact factor: 2.698

4.  Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers.

Authors:  S J Healy; J J Heffron; M Lehane; D G Bradley; K Johnson; T V McCarthy
Journal:  BMJ       Date:  1991-11-16

Review 5.  Stressed out: the skeletal muscle ryanodine receptor as a target of stress.

Authors:  Andrew M Bellinger; Marco Mongillo; Andrew R Marks
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

6.  Abnormal ryanodine receptor channels in malignant hyperthermia.

Authors:  M Fill; R Coronado; J R Mickelson; J Vilven; J J Ma; B A Jacobson; C F Louis
Journal:  Biophys J       Date:  1990-03       Impact factor: 4.033

7.  Evidence for genetic heterogeneity of malignant hyperthermia susceptibility.

Authors:  T Deufel; A Golla; D Iles; A Meindl; T Meitinger; D Schindelhauer; A DeVries; D Pongratz; D H MacLennan; K J Johnson
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

Review 8.  Molecular tools to elucidate problems in excitation-contraction coupling.

Authors:  D H MacLennan
Journal:  Biophys J       Date:  1990-12       Impact factor: 4.033

Review 9.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

Review 10.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.